Prostate health is an important concern for men. The prostate is a small gland that is part of the male reproductive system. It is located just below the bladder and in front of the rectum. Its primary function is to produce fluid that transports sperm during ejaculation. Prostate health is important for a number of reasons.
An enlarged prostate can cause discomfort and can lead to urinary problems such as frequent urination, difficulty urinating, or a weak urine stream. An enlarged prostate can also increase the risk of prostate cancer. Other risks for prostate cancer include age, family history, and ethnicity.
There are a number of steps men can take to promote prostate health and reduce their risk of prostate cancer. Eating a balanced diet and engaging in regular physical activity can help keep the prostate healthy. Additionally, men should have a yearly prostate exam to check for any signs of prostate cancer.
According to a research report "Prostate Health Market by Disease Indication (Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate Hyperplasia (BPH), Tamsulosin, 5 Alpha Reductase, Prostatitis, OTC, Prescription (Rx), Region (NA, Europe, APAC) - Global Forecasts to 2026" published by MarketsandMarkets, the global prostate health market is projected to reach USD 48.9 billion by 2026 from USD 31.8 billion in 2021, at a CAGR of 9.0% during the forecast period.
Request for assumptions how numbers were triangulated.
https://www.marketsandmarkets.com/requestsampleNew.asp?id=107055093
Market Growth Drivers
- Growing prevalence of prostate cancer and BPH
Market Growth Opportunities
- Emerging economies (such as China, India, Brazil, and Mexico) are projected to offer significant growth opportunitie
Market Challenges
- Low awareness regarding prostate health among men
Industry Trends
- This represents an annual growth of about 7% and a total increase of 58% from 2010. Obesity and Benign Prostatic Hyperplasia (BPH) are closely associated.
Finasteride and Dutasteride (among other 5-ARIs) convert testosterone to dihydrotestosterone. These drugs also decrease the synthesis of several neuroactive steroids, but the modulation of the neuroendocrine stress response may lead to depression. Other side effects of 5-ARIs are gynecomastia, impotence, and reduced libido and ejaculate volume.
Download an Illustrative Overview:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107055093
Some of the prominent players operating in the prostate health market are Eli Lilly and Company (US), Pfizer Inc. (US), Merck Co., Inc. (US), GlaxoSmithKline plc. (UK), Abbott (US), and Astellas Pharma Inc. (Japan), and other players.
Research Developments
- In March 2022, Lantheus Holdings, Inc. (US) collaborated with Novartis AG (Switzerland) to include PYLARIFY (piflufolastat F18) in prostate cancer clinical trials with Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to support prostate cancer clinical development.
- In March 2022, Novartis AG (Switzerland) received approval for PluvictoTM (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) by FDA for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigenndash;positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC).
- In January 2021, Pharex Tamsulosin for the treatment of benign prostatic hyperplasia was introduced by PHAREX Health Corporation (Philippines) in collaboration with the Philippine Urological Association (PUA).
- In October 2020, Israeli medical device manufacturer Butterfly Medical raised USD 7 million in a Series B round to develop an anatomically shaped nitinol implant positioned in the prostatic urethra to relieve BPH symptoms
Content Source:
1. https://www.prnewswire.com/news-releases/prostate-health-market-worth-48-9-billion-by-2026--exclusive-report-by-marketsandmarkets-301443961.html
